SPC365

Manta versus ProGlide in vascular closure of transfemoral TAVI

Session: Posters (Sessão 6 - Écran 2) - Intervenção não coronária
Speaker: André Grazina

Congress: CPC 2023
Topic: H. Interventional Cardiology and Cardiovascular Surgery
Theme: 25. Interventional Cardiology
Subtheme: 25.3 Non-coronary Cardiac Intervention
Session Type: Pósters Electrónicos
FP Number: ---
Authors: André Grazina; Bárbara Lacerda Teixeira; Alexandra Castelo; André Ferreira; Francisco Barbas Albuquerque; Ana Raquel Santos; Tiago Mendonça; Inês Rodrigues; Ruben Ramos; António Fiarresga; Duarte Cacela; Rui Cruz Ferreira

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">Introduction:</span></strong> <span style="background-color:white"><span style="color:black">Transfemoral (TF) access is globally accepted as the preferential route for transcatheter aortic valve implantation (TAVI). The use of large bore introducer sheaths (14-16 Fr) is often associated with vascular complications, the main one difficult hemostasis. </span></span>Several vascular closing devices (VCD) with different mechanisms have been developed with proven efficacy, but comparative analysis is lacking.</span></span></p>

<p style="text-align:justify">&nbsp;</p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">Objectives:</span></strong><span style="color:black"> This analysis aims to compare outcomes in patients that used pure plug-based technique (Manta</span><span style="font-family:Symbol"><span style="color:black">&auml;</span></span><span style="color:black">, Teleflex) versus primary suture-based technique (ProGlide</span><span style="font-family:Symbol"><span style="color:black">&auml;</span></span><span style="color:black">, Abbott Vascular) vascular closure devices.</span></span></span></p>

<h1 style="text-align:justify"><span style="font-size:24pt"><span style="font-family:&quot;Times New Roman&quot;,serif"><span style="font-size:11.0pt"><span style="font-family:&quot;Calibri&quot;,sans-serif"><span style="color:black">Methods: </span></span></span><span style="font-size:11.0pt"><span style="font-family:&quot;Calibri&quot;,sans-serif"><span style="color:black">Retrospective analysis of patients submitted to TAVI in a single tertiary center. Only TAVI procedures through transfemoral access route were included. Patients in which was used the suture-based technique Prostar</span></span></span><span style="font-size:11.0pt"><span style="font-family:Symbol"><span style="color:black">&auml;</span></span></span><span style="font-size:11.0pt"><span style="font-family:&quot;Calibri&quot;,sans-serif"><span style="color:black"> were excluded from this analysis. The assessed endpoints were 30-day all-cause mortality, 30-day major/ life-threatening bleeding, 30-day vascular complication (criteria according to Valve Academic Research Consortium-2), post-procedural hemoglobin drop and post-procedural hospital length. </span></span></span></span></span></h1>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="background-color:white"><span style="color:black">Results:</span></span></strong> <span style="background-color:white"><span style="color:black">368 transfemoral TAVI procedures were included in this analysis (mean age 82.3 years-old, 58% female). 29.3% (n 108) of patients used a pure plug-based VCD Manta and 70.1% (n 260) used the primary-suture based VCD ProGlide</span></span><span style="color:black">. Baseline characteristics were similar between the two groups (table 1). Regarding outcomes, there was no evidence of statistically significant differences in 30-day mortality (5.6% vs 5.0%, p0.826), 30-day major/life-threatening bleeding (8.3% vs 8.1%, p0.935), 30-day vascular complication (14.8% vs 14.2%, p0.884), 30-day major vascular complication (8.3% vs 5.0%, p0.219), median post-procedural hemoglobin drop (1.8g/dL vs 1.9g/dL, p0.837) and pos-procedural hospital length (6 days vs 7 days, p0.005).</span></span></span></p>

<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="background-color:white"><span style="color:black">Conclusions:</span></span></strong> <span style="background-color:white"><span style="color:black">In patients submitted to transfemoral TAVI, a pure plug-based VCD strategy using Manta system has similar results to a primary suture based VCD strategy using ProGlide system but is associated with a smaller post-procedural hospital length stay. </span></span></span></span></p>